Skip to main content

Advertisement

Log in

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Limited information is available regarding the usefulness of third-line chemotherapy for recurrent ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-taxane regimens as first-line therapy.

Patients and methods

We retrospectively reviewed the medical records of women with ovarian, fallopian tube, and primary peritoneal cancer who were treated at the National Cancer Center Hospital between 1999 and 2005 to investigate the relations of clinicopathological factors to important clinical endpoints such as the response rate (RR), time to progression (TTP) and overall survival (OS) after third-line chemotherapy.

Results

A total of 172 patients received first-line platinum/taxane regimens during the study period, among whom 111 had disease progression after first-line chemotherapy. Eighty-one of these 111 patients received second-line chemotherapy, and 73 had disease progression. Fifty-four of the 73 patients with disease progression received third-line chemotherapy. The RR to third-line chemotherapy was 40.7% (95% CI, 27.6–53.8%). The median TTP was 4.4 months (range 0–19.5 months), and the median OS was 10.4 months (range 1.5–44.3 months). Performance status (PS) and primary drug-free interval (DFI) were independent predictive factors for the RR to third-line chemotherapy (P = 0.04 and P = 0.009). PS and primary DFI were also independent predictive factors for TTP and OS on multivariate analysis (P = 0.006, = 0.005 and P = 0.01, = 0.004, respectively).

Conclusions

PS and primary DFI are useful predictors of the response to third-line chemotherapy in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. In this setting, however, both of these variables are subject to several well-established potential biases and limitations; further prospective studies are thus needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653

    PubMed  CAS  Google Scholar 

  • Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21:149s–167s

    Article  PubMed  Google Scholar 

  • Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC (2002) Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 86:200–211

    Article  PubMed  Google Scholar 

  • Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274

    PubMed  CAS  Google Scholar 

  • Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963–968

    Article  PubMed  CAS  Google Scholar 

  • Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Holzel D (2002) Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38:2435–2445

    Article  PubMed  CAS  Google Scholar 

  • Findley MK, Lee H, Seiden MV, Shah MA, Fuller AF, Goodman A, Penson RT (2005) Do more lines of chemotherapy make you live longer? Treatment for ovarian cancer comparing cohorts of patients 1989-90 with 1995-6 in multivariate analysis of survival. J Clin Oncol 23(Suppl):16S

    Google Scholar 

  • Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B (2002) Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum—a systematic review of the evidence from randomized trials. Eur J Gynaecol Oncol 23:104–110

    PubMed  Google Scholar 

  • Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15–36

    Article  PubMed  CAS  Google Scholar 

  • Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the ovary. J Epidemiol Biostat 6:107–138

    PubMed  CAS  Google Scholar 

  • Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003. CA Cancer J Clin 53:5–26

    Article  PubMed  Google Scholar 

  • Markman M (1998) ‘‘Recurrence within 6 months of platinum- therapy’’: an adequate definition of ‘‘platinum-refractory’’ ovarian cancer? Gynecol Oncol 69:91–92

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393

    PubMed  CAS  Google Scholar 

  • Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1998) Evidence that a ‘‘treatment-free interval of less than 6 months’’ does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 124:326–328

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141

    PubMed  CAS  Google Scholar 

  • Rocconi RP, Case AS, Staughn JM Jr, Estes JM, Partridge EE (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effective analysis. Cancer 107:536–543

    Article  PubMed  CAS  Google Scholar 

  • Tangjitgamol S, See HT, Manusirvithaya S, Levenback CF, Gershenson DM, Kavanagh JJ (2004) Third-line chemotherapy in platinum-and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 12:804–814

    Article  Google Scholar 

  • Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71:1559–1564

    PubMed  CAS  Google Scholar 

  • Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 12:1748–1753

    PubMed  CAS  Google Scholar 

  • Villa A, Parazzini F, Scarfone G, Guarnerio P, Bolis G (1999) Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients. Br J Cancer 79:373–374

    PubMed  CAS  Google Scholar 

  • Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, Peterson G, Markman M (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126–3129

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by The Supporting Fund of Obstetrics and Gynecology Kurume University.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shin Nishio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nishio, S., Katsumata, N., Matsumoto, K. et al. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. J Cancer Res Clin Oncol 135, 551–557 (2009). https://doi.org/10.1007/s00432-008-0488-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0488-x

Keywords

Navigation